Five-year experience in providing infectious safety of donor blood and its components gained by the blood center of the RT Federal medical-biological agency

View or download the full article: 
PDF icon health-risk-analysis-2022-3-10.pdf
UDC: 
61
DOI: 
10.21668/health.risk/2022.3.10.eng
Authors: 

А.А. Filippova1,2, А.P. Faenko1,2, S.А. Golosova1,2, I.V. Ivanova1,2, Е.А. Klyueva1,2, Ya.N. Glazov1,2, D.S. Malysheva1, М.А. Kasatkin1,2

Organization: 

1The FMBA Blood Center, bldg 2, 6 Shchukinskaya Str., Moscow, 123182, Russian Federation
2The FMBA Federal Research and Clinical Center for Specialized Medical Aid and Medical Technologies, 91 Volokolamskoe Ave., Moscow, 125371, Russian Federation

Abstract: 

Screening technologies aimed at identifying such transfusion transmissible infections (TTI) as hepatitis B and C, HIV-1,2 and syphilis have been developing and this has resulted in increased safety of applied hemotherapy.

Our research goal was to analyze detection of infectious markers in donors of the FMBA Blood Center over five years.
We examined 167,389 samples of donor blood taken from 53,093 donors of blood and its components by the FMBA Blood Center over the period from 2015 to 2019.

Over the whole analyzed period, we detected 1453 infectious-positive samples taken from 1235 donors. Average long-term quantity of detected hepatitis C markers equaled 78.6 ± 9.4; hepatitis B, 49.8 ± 8.2; syphilis, 66.2 ± 16.8; HIV, 52.8 ± 13.2. We also analyzed detected of TTI markers in long-term dynamics and established an ascending trend in a number of syphilis markers (the growth rate was 3.2), hepatitis B (the growth rate was 2.5), and a descending trend in hepatitis C markers (the decrease rate was 3.3) as well as HIV markers (the decrease rate was 1.7). This decrease rate in detection of HIV markers (fall by 1.7) occurred both among first-time and regular donors. At the same time, we revealed growing detection of syphilis markers both among first-time donors where it grew by 3.6 and among regular ones, by 1.4. Frequency of infection markers was higher among first-time donors than among regular ones as per syphilis markers, 2.351 (95 % CI: 1.862–2.938), p < 0.00001; hepatitis B markers, 2.111 (95 % CI: 1.622–2.763), p < 0.00001; hepatitis C markers, 2.107 (95 % CI: 1.708–2.609), p < 0.00001; and HIV, 2.471 (95 % CI: 1.9–3.238), p < 0.00001.

Over the last 5 years, there was a descending trend in detection of transfusion transmissible infections among donors regarding HIV and viral hepatitis C excluding tests aimed at detecting syphilis and viral hepatitis B markers.

Keywords: 
Blood service, blood donors, transfusion transmissible infections, HIV, hepatitis, syphilis, viral hepatitis B, viral hepatitis С, infections markers screening, infectious safety of blood transfusions
Filippova А.А., Faenko А.P., Golosova S.А., Ivanova I.V., Klyueva Е.А., Glazov Ya.N., Malysheva D.S., Kasatkin М.А. Five-year experience in providing infectious safety of donor blood and its components gained by the blood center of the rf federal medical-biological agency. Health Risk Analysis, 2022, no. 3, pp. 110–118. DOI: 10.21668/health.risk/2022.3.10.eng
References: 
  1. Hall W.H., Desforges J., Athari F., Cooper S.P., Johnson C.S., Lemon S., Lindsay K., McCullough J. [et al.]. Infectious disease testing for blood transfusions. NIH Consensus Statement, 1995, vol. 13, no. 1, pp. 1–27. DOI: 10.1001/JAMA.274.17.1374
  2. Gardella C., Marfin A.A., Kahn R.H., Swint E., Markowitz L.E. Persons with early syphilis identified through blood or plasma donation screening in the United States. J. Infect. Dis., 2002, vol. 185, no. 4, pp. 545–549. DOI: 10.1086/338829
  3. Orton S. Syphilis and blood donors: what we know, what we do not know, and what we need to know. Transfus. Med. Rev., 2001, vol. 15, no. 4, pp. 282–291. DOI: 10.1053/tmrv.2001.26956
  4. Kaur G., Kaur P. Syphilis testing in blood donors: an update. Blood Transfus., 2015, vol. 13, no. 2, pp. 197–204. DOI: 10.2450/2014.0146-14
  5. De Schryver A., Meheus A. Syphilis and blood transfusion: a global perspective. Transfusion, 1990, vol. 30, no. 9, pp. 844–847. DOI: 10.1046/j.1537-2995.1990.30991048793.x
  6. Van der Sluis J.J., ten Kate F.J.W., Vuzevski V.D., Kothe F.C., Aelbers G.M., van Eijk R.V. Transfusion syphilis, survival of Treponema pallidum in stored donor blood. II. Dose dependence of experimentally determined survival times. Vox Sang., 1985, vol. 49, no. 6, pp. 390–399.
  7. Walker R.H. The disposition of STS reactive blood in a transfusion service. Transfusion, 1965, vol. 5, no. 5, pp. 452–456. DOI: 10.1111/j.1537-2995.1965.tb02924.x
  8. Jenum P.A., Flesland Ø., Blystad H., Samdal Vik I.S., Hervig T., Maeland A., Saeter G. Syfilis og blodtransfusjon [Syphilis and blood transfusion]. Tidsskr. Nor. Laegeforen., 2010, vol. 130, no. 8, pp. 839–841. DOI: 10.4045/tidsskr.08.0188 (in Norwegian).
  9. Attaullah S., Khan S., Khan J. Trend of transfusion transmitted infections frequency in blood donors: provide a road map for its prevention and control. J. Transl. Med., 2012, vol. 10, pp. 20. DOI: 10.1186/1479-5876-10-20
  10. Busch M.P., Bloch E.M., Kleinman S. Prevention of transfusion-transmitted infections. Blood, 2019, vol. 133, no. 17, pp. 1854–1864. DOI: 10.1182/blood-2018-11-833996
  11. Perkins H.A., Busch M.P. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion, 2010, vol. 50, no. 10, pp. 2080–2099. DOI: 10.1111/j.1537-2995.2010.02851.x
  12. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood, 2008, vol. 112, no. 7, pp. 2617–2626. DOI: 10.1182/blood-2008-07-077370
  13. Feinstone S.M., Kapikian A.Z., Purcell R.H., Alter H.J., Holland P.V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med., 1975, vol. 292, no. 15, pp. 767–770. DOI: 10.1056/NEJM197504102921502
  14. Alter H.J., Houghton M. Clinical Medical Research Award. Hepatitis C virus and eliminating post‐transfusion hepa-titis. Nat. Med., 2000, vol. 6, no. 10, pp. 1082–1086. DOI: 10.1038/80394
  15. Hoofnagle J.H., Seeff L.B., Bales Z.B., Zimmerman H.J. Type B hepatitis after transfusion with blood containing anti-body to hepatitis B core antigen. N. Engl. J. Med., 1978, vol. 298, no. 25, pp. 1379–1383. DOI: 10.1056/NEJM197806222982502
  16. Glynn S.A., Busch M.P., Dodd R.Y., Katz L.M., Stramer S.L., Klein H.G., Simmons G., Kleinman S.H. [et al.]. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion, 2013, vol. 53, no. 2, pp. 438–454. DOI: 10.1111/j.1537-2995.2012.03742.x
  17. Kuo G., Choo Q.L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell R.H., Miyamura T., Dienstag J.L. [et al.]. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, vol. 244, no. 4902, pp. 362–364. DOI: 10.1126/science.2496467
  18. Centers for Disease Control (CDC). Possible transfusion-associated acquired immune deficiency syndrome (AIDS) – California. MMWR Morb. Mortal. Wkly Rep., 1982, vol. 31, no. 48, pp. 652–654.
  19. Curran J.W., Lawrence D.N., Jaffe H., Kaplan J.E., Zyla L.D., Chamberland M., Weinstein R., Lui K.J. [et al.]. Ac-quired immunodeficiency syndrome (AIDS) associated with transfusions. N. Engl. J. Med., 1984, vol. 310, no. 2, pp. 69–75. DOI: 10.1056/NEJM198401123100201
  20. Tyler J.P., Dobler K.J., Driscoll G.L., Stewart G.J. The impact of AIDS on artificial insemination by donor. Clin. Re-prod. Fertil., 1986, vol. 4, no. 5, pp. 305–317.
  21. Busch M.P., Young M.J., Samson S.M., Mosley J.W., Ward J.W., Perkins H.A. Risk of human immunodeficiency vi-rus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion, 1991, vol. 31, no. 4, pp. 4–11. DOI: 10.1046/j.1537-2995.1991.31191096183.x
  22. Simon T.L., Bankhurst A.D. A pilot study of surrogate tests to prevent transmission of acquired immune deficiency syndrome by transfusion. Transfusion, 1984, vol. 24, no. 5, pp. 373–378. DOI: 10.1046/j.1537-2995.1984.24585017822.x
  23. Kaplan H., Kleinman S. Infection, immunity, and blood transfusion. In: R.Y. Dodd, L. Barker eds. XVIth Annual Sci-entific Symposium of the American Red Cross. Washington DC, May 9–11, 1984, pp. 297–308.
  24. Glynn S.A., Kleinman S.H., Wright D.J., Busch M.P., NHLBI Retrovirus Epidemiology Donor Study. International application of the incidence rate/window period model. Transfusion, 2002, vol. 42, no. 8, pp. 966–972. DOI: 10.1046/j.1537-2995.2002.00200.x
  25. Petersen L.R., Satten G.A., Dodd R., Busch M., Kleinman S., Grindon A., Lenes B. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion, 1994, vol. 34, no. 4, pp. 283–289. DOI: 10.1046/j.1537-2995.1994.34494233574.x
  26. Zou S., Dorsey K.A., Notari E.P., Foster G.A., Krysztof D.E., Musavi F., Dodd R.Y., Stramer S.L. Prevalence, inci-dence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion, 2010, vol. 50, no. 7, pp. 1495–1504. DOI: 10.1111/j.1537-2995.2010.02622.x
  27. Chechetkin A.V., Danilchenko V.V., Grigorjan M.S., Vorobey L.G., Plotskiy R.A., Makeev A.B. The activity of the blood service in the Russian Federation in 2016. Transfuziologiya, 2017, vol. 18, no. 3, pp. 4–14 (in Russian).
  28. Chechetkin A.V., Danilchenko V.V., Grigorjan M.S., Vorobey L.G., Plotskiy R.A. Indicators of activity of the blood service in the Russian Federation in 2018. Transfuziologiya, 2019, vol. 20, no. 3, pp. 160–170 (in Russian).
  29. Bubnova L.N., Matveeva T.A., Berkos M.V., Chechetkin A.V. Transfusion transmitted infections in regular and first-time donors of blood and blood components. Transfuziologiya, 2015, vol. 16, no. 4, pp. 24–32 (in Russian).
  30. Kubanov A.A., Bogdanova E.V. Dynamics of the incidence of sexually transmitted infections in different groups of the adult population in the Russian Federation in 2011–2019. Infektsionnye bolezni, 2020, vol. 18, no. 4, pp. 58–73. DOI: 10.20953/1729-9225-2020-4-58-73
  31. Candotti D., Boizeau L., Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfus. Clin. Biol., 2017, vol. 24, no. 3, pp. 189–195. DOI: 10.1016/j.tracli.2017.06.014
Received: 
17.05.2022
Approved: 
19.08.2022
Accepted for publication: 
21.09.2022

You are here

Home